Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/14/2846684/0/en/Larimar-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Operating-and-Financial-Results-and-Provides-Update-on-Nomlabofusp-Development.html
https://www.globenewswire.com//news-release/2024/03/11/2844141/0/en/Larimar-Therapeutics-Announces-the-Dosing-of-the-First-Patient-in-Long-term-Open-Label-Extension-Study-for-Nomlabofusp-in-Patients-with-Friedreich-s-Ataxia.html
https://www.globenewswire.com//news-release/2024/03/06/2841766/0/en/Larimar-Therapeutics-to-Present-at-the-Leerink-Partners-Global-Biopharma-Conference.html
https://www.globenewswire.com//news-release/2024/02/16/2830942/0/en/Larimar-Therapeutics-Announces-Closing-of-Underwritten-Public-Offering-of-Common-Stock-and-Exercise-in-Full-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com//news-release/2024/02/14/2828927/0/en/Larimar-Therapeutics-Announces-Pricing-of-Underwritten-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/02/13/2828666/0/en/Larimar-Therapeutics-Announces-Proposed-Underwritten-Public-Offering.html
https://endpts.com/larimar-therapeutics-shares-key-biomarker-data-aims-for-accelerated-approval-for-friedreichs-ataxia-drug/
https://www.globenewswire.com//news-release/2023/11/14/2779905/0/en/Larimar-Therapeutics-Reports-Third-Quarter-2023-Operating-and-Financial-Results.html
https://www.globenewswire.com//news-release/2023/11/01/2771692/0/en/Larimar-Therapeutics-to-Present-at-the-Guggenheim-5th-Annual-Inflammation-Neurology-Immunology-Conference.html
https://www.globenewswire.com//news-release/2023/10/03/2754158/0/en/Larimar-Therapeutics-Appoints-Dr-Jeffery-W-Sherman-to-its-Board-of-Directors.html